Advertisement

Pharmacy World and Science

, Volume 27, Issue 6, pp 432–435 | Cite as

Treatment of Gastroesophageal Reflux Disease*

  • Michael PettitEmail author
Review Article

Abstract

Aim of the review and methods:

This review brings together information on the treatment of gastroesophageal reflux disease. Published manuscripts were identified from Medline. The articles were then screened for relevance prior to inclusion in the review.

Results and conclusion:

Up to 40% of people in Western countries are estimated to regularly experience heartburn, the most characteristic symptom of gastroesophageal reflux disease (GERD). Treatment options available for GERD range from over-the-counter (OTC) antacids to proton pump inhibitors (PPIs) and anti-reflux surgery. Many patients self-medicate with OTC medications such as antacids and low-dose histamine H2-receptor antagonists (H2RA) to relieve episodic or food-related symptoms of GERD, and may not seek medical advice unless symptoms persist or worsen. However, GERD is a chronic disease that frequently affects health-related quality of life and, if not properly managed, the complications of GERD may include erosive oesophagitis (EO), Barrett’s oesophagus and adenocarcinoma.

Adequate control of acid secretion is key to the successful treatment of the condition. OTC medications provide effective symptom relief to about one quarter of patients suffering from GERD. H2RAs can also provide effective symptomatic relief, particularly in patients with milder GERD, but become less-effective over time. PPIs are the agents of choice for the suppression of gastric acid production and have become the mainstay of therapy for acid-related diseases. PPIs produce significantly faster and more complete symptomatic relief, significantly faster and more complete healing of erosive GERD compared with H2RAs and are also significantly more effective at preventing relapse of EO.

There are a number of existing guidelines for the treatment of GERD. Recommendation for initial therapy consist of general measures, such as lifestyle advice in combination with antacids and/or alginates. When general measures fail, the next step is empirical therapy. Two options exist for the expirical treatment of GERD, so-called “step-up” or “step-down” therapy. There are no clear data to support either treatment strategy as a universal approach to all patients; consequently, physicians must always choose the course best suited to the individual patient.

Keywords

Acid supression Gastroesophageal reflux disease Management Therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Heading, RC 1989Epidemiology of oesophageal reflux diseaseScand J Gastroenterol Suppl168337PubMedGoogle Scholar
  2. 2.
    Spechler, SJ 1992Epidemiology and natural history of gastro-oesophageal reflux diseaseDigestion51249PubMedGoogle Scholar
  3. 3.
    Hollenz, M, Stolte, M, Labenz, J 2002Prävalenz der Refluxkrankheit in einer AllgemeinpraxisDtsch Med Wochenschr127100712CrossRefPubMedGoogle Scholar
  4. 4.
    DiPalma, JA 2001Management of severe gastroesophageal reflux diseaseJ Clin Gastroenterol321926CrossRefPubMedGoogle Scholar
  5. 5.
    Behar, J, Sheahan, DG, Biancani, P, Spiro, HM, Storer, EH 1975Medical and surgical management of reflux esophagitis. A 38-month report of a prospective clinical trialN Engl J Med2932638PubMedCrossRefGoogle Scholar
  6. 6.
    Lieberman, DA 1987Medical therapy for chronic reflux esophagitis. Long-term follow-upArch Intern Med147171720CrossRefPubMedGoogle Scholar
  7. 7.
    Huang, JQ, Hunt, RH 2001Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physicianBest Pract Res Clin Gastro- enterol1535570Google Scholar
  8. 8.
    Colin-Jones, DG 1995The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux diseaseAliment Pharmacol Ther9914PubMedGoogle Scholar
  9. 9.
    Olbe L, Cederberg C, Lind T, Olausson M. Effect of omeprazole on gastric acid secretion and plasma gastrin in man. Scand J Gastroenterol Suppl 1989; 166: 27–32; discussion 41–2Google Scholar
  10. 10.
    Wilder-Smith, CH, Ernst, T, Gennoni, M,  et al. 1990Tolerance to oral H2-receptor antagonistsDig Dis Sci3597683CrossRefPubMedGoogle Scholar
  11. 11.
    Wilder-Smith, C, Halter, F, Ernst, T,  et al. 1990Loss of acid suppression during dosing with H2-receptor antagonistsAliment Pharmacol Ther41527PubMedGoogle Scholar
  12. 12.
    Hatlebakk, JG, Berstad, A 1996Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitisScand J Gastroenterol3195458PubMedGoogle Scholar
  13. 13.
    Lachman, L, Howden, CW 2000Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administrationAm J Gastroenterol955761CrossRefPubMedGoogle Scholar
  14. 14.
    Bell, NJ, Burget, D, Howden, CW,  et al. 1992Appropriate acid suppression for the management of gastro-oesophageal reflux diseaseDigestion515967PubMedGoogle Scholar
  15. 15.
    Tytgat, GN 1987Clinical efficacy of sucralfate in reflux esophagitis. Comparison with cimetidineAm J Med833842PubMedGoogle Scholar
  16. 16.
    Chiba, N, Gara, CJ, Wilkinson, JM, Hunt, RH 1997Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysisGastroenterology1121798810CrossRefPubMedGoogle Scholar
  17. 17.
    Castell, DO, Brunton, SA, Earnest, DL,  et al. 1998GERD: management algorithms for the primary care physician and the specialistPract Gastroenterol221846Google Scholar
  18. 18.
    Dent, J, Brun, J, Fendrick, AM,  et al. 1999An evidence-based appraisal of reflux disease management – the Genval Workshop ReportGut44S1S16Google Scholar
  19. 19.
    Hunt, RH 1995The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux diseaseAliment Pharmacol Ther937PubMedGoogle Scholar
  20. 20.
    Bardhan, KD 1996Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy – a sideways glance YaleJ Biol Med6921124Google Scholar
  21. 21.
    Chiba, N 1997Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overviewCan J Gastroenterol1166B73BPubMedGoogle Scholar
  22. 22.
    Johnson, DA, Benjamin, SB, Vakil, NB,  et al. 2001Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safetyAm J Gastroenterol962734CrossRefPubMedGoogle Scholar
  23. 23.
    Vakil, NB, Shaker, R, Johnson, DA,  et al. 2001The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safetyAliment Pharmacol Ther1592735PubMedGoogle Scholar
  24. 24.
    DeVault, KR, Castell, DO 1995Guideliness for the diagnosis and treatment of gastroesophageal reflux diseaseArch Intern Med155216573CrossRefPubMedGoogle Scholar
  25. 25.
    DeVault, KR, Castell, DO 1999Updated guidelines for the diagnosis and treatment of gastroesphageal reflux diseaseAm J Gastroenterol94143442CrossRefPubMedGoogle Scholar
  26. 26.
    NICE guideline. Dyspepsia: management of dyspepsia in adults in primary care. Available from:http://www.nice.org.uk/page. aspx?o=105765; February 2004
  27. 27.
    Katelaries, P, Holloway, R, Talley, N,  et al. 2002Gastro-oesophageal reflux diease in adults: guidelines for cliniciansJ Gastroenterol Hepatol1782533Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.Clinical Pharmacy Unit, Royal Sussex Country HospitalUniversity of BrightonBrightonUK

Personalised recommendations